Acute migraine therapy: Recent evidence from randomized comparative trials

Current Opinion in Neurology

Volumn 21, Issue 3, 2008, Pages 331-337

  Mett, Anna ^a,b   Tfelt Hansen, Peer ^c  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; CAFFEINE; CAFFEINE DERIVATIVE; CAFFEINE PLUS INDOMETHACIN PLUS PROCHLORPERAZINE; ELETRIPTAN; ERGOTAMINE; IBUPROFEN; KETOPROFEN; METOCLOPRAMIDE; NAPROXEN; NAPROXEN PLUS SUMATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

ANALGESIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HUMAN; META ANALYSIS; MIGRAINE; MONOTHERAPY; NAUSEA; NEUROTOXICITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIEMETICS; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG THERAPY, COMBINATION; ERGOTAMINE; HUMANS; INDOMETHACIN; MIGRAINE DISORDERS; PROCHLORPERAZINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN AGONISTS; TREATMENT OUTCOME; TRYPTAMINES; VASOCONSTRICTOR AGENTS;

EID: 43249099808     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3282fee843     Document Type: Review

References (38)

1. Diener HC, Katsarava Z, Limmroth V. [Current diagnosis and treatment of migraine]. Schmerz 2008.
2. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population - a prevalence study. J Clin Epidemiol 1991; 44:1147-1157.
3. Berg J, Ramadan NM, Societal burden of headache, in The Headaches, J. Olesen, et al., Editors. 2006, Lippincott Williams & Wilkins: Philadelphia. p. 35-42.
4. Dahlöf C, Solomon G, Impact of the headache on the individual and family, in The Headaches, J. Olesen, et al., Editors. 2006, Lippincott Williams & Wilkins: Philadelphia. p. 27-34.
5. Leonardi M, Steiner TJ, Scher AT, Lipton RB. The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). J Headache Pain 2005; 6:429-440.
6. Engindeniz Z, Demircan C, Karli N, et al. Intramuscular tramadol vs. diclofenac sodium for the treatment of acute migraine attacks in emergency department: a prospective, randomised, double-blind study. J Headache Pain 2005; 6:143-148.
7. Goadsby PJ. Migraine pathophysiology. Headache 2005; 45 Suppl 1:S14-24.
8. Moskowitz MA. Pathophysiology of headache-past and present. Headache 2007; 47 Suppl 1:S58-63.
9. Diener HC, Jansen JP, Reches A, et al. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. Eur Neurol 2002; 47:99-107.
10. Villalon CM, Centurion D, Valdivia LF, et al. Migraine: pathophysiology, pharmacology, treatment and future trends. Curr Vasc Pharmacol 2003; 1:71-84.
11. Tfelt-Hansen P, Saxena PR, Dahlof C, et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain 2000; 123 (Pt 1):9-18.
12. Geraud G, Compagnon A, Rossi A. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study. Eur Neurol 2002; 47:88-98.
13. Snow V, Weiss K, Wall EM, Mottur-Pilson C. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med 2002; 137:840-849.
14. Di Monda V, Nicolodi M, Aloisio A, et al. Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine versus sumatriptan in acute treatment of multiple migraine attacks: a multicenter, randomized, crossover trial. Headache 2003; 43:835-844.
15. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358:1668-1675.
16. Tfelt-Hansen P, Steiner TJ. Over-the-counter triptans for migraine: what are the implications? CNS Drugs 2007; 21:877-883.
17. Landy S, Smith T. Standards of care for headache diagnosis and treatment. Treatment of primary headache: acute migraine treatment. National Headache Foundation 2004:27-39.
18. Goadsby PJ, Massiou H, Pascual J, et al. Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurol Scand 2007; 115:34-40.
19. Gladstone JP, Dodick DW. Acute migraine: which triptan? Pract Neurol 2004; 4:6-19.
20. Colman I, Rothney A, Wright SC, et al. Use of narcotic analgesics in the emergency department treatment of migraine headache. Neurology 2004; 62:1695-1700.
21. Diener HC, Limmroth V. Analgesics. Curr Med Res Opin 2001; 17 Suppl 1:s13-16.
22. Saxena PR, Tfelt-Hansen P, Triptans, 5HT1B/1B agonists, in the acute treatment of migraine, in The Headaches, J. Olesen, et al., Editors. 2006, Lippincott Williams & Wilkins: Philadelphia.
23. Buzzi MG, Dimitriadou V, Theoharides TC, Moskowitz MA. 5-Hydroxytryptamine receptor agonists for the abortive treatment of vascular headaches block mast cell, endothelial and platelet activation within the rat dura mater after trigeminal stimulation. Brain Res 1992; 583:137-149.
24. Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990; 99:202-206.
25. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33:48-56.
26. Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA 2007; 297:1443-1454.
27. Smith TR, Sunshine A, Stark SR, et al. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache 2005; 45:983-991.
28. Rozen TD, Swanson JW, Stang PE, et al. Increasing incidence of medically recognized migraine headache in a United States population. Neurology 1999; 53:1468-1473.
29. Tfelt-Hansen P, Block G, Dahlof C, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000; 20:765-786.
30. Dib M, Massiou H, Weber M, et al. Efficacy of oral ketoprofen in acute migraine: a double-blind randomized clinical trial. Neurology 2002; 58:1660-1665.
31. Diener HC, Bussone G, de Liano H, et al. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia 2004; 24:947-954.
32. Dowson AJ, Massiou H, Lainez JM, Cabarrocas X. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia 2002; 22:453-461.
33. Sandrini G, Cerbo R, Del Bene E, et al. Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, multicentre study. Int J Clin Pract 2007; 61:1256-1269.
34. Saper J, Dahlof C, So Y, et al. Rofecoxib in the acute treatment of migraine: a randomized controlled clinical trial. Headache 2006; 46:264-275.
35. Spierings EL, Gomez-Mancilla B, Grosz DE, et al. Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison. Arch Neurol 2001; 58:944-950.
36. Goadsby PJ. A triptan too far? J Neurol Neurosurg Psychiatry 1998; 64:143-147.
37. Lainez MJ, Galvan J, Heras J, Vila C. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur J Neurol 2007; 14:269-275.
38. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine - report of an EFNS task force. Eur J Neurol 2006; 13:560-572.